Dong-A Socio Holdings Valuation

Is A000640 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A000640 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A000640 (₩113500) is trading above our estimate of fair value (₩1385.97)

Significantly Below Fair Value: A000640 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A000640?

Key metric: As A000640 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for A000640. This is calculated by dividing A000640's market cap by their current earnings.
What is A000640's PE Ratio?
PE Ratio	13.9x
Earnings	₩51.02b
Market Cap	₩709.46b

A000640 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.1x
Enterprise Value/EBITDA	8.3x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does A000640's PE Ratio compare to its peers?

The above table shows the PE ratio for A000640 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	16.9x
A003850 Boryung	10.7x	9.9%	₩688.3b
A086450 DongKook Pharmaceutical	14.2x	14.4%	₩773.0b
A214370 Caregen	25.7x	14.1%	₩869.7b
A001060 JW Pharmaceutical	17x	29.4%	₩600.1b
A000640 Dong-A Socio Holdings	13.9x	n/a	₩709.5b

Price-To-Earnings vs Peers: A000640 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the peer average (16.9x).

Price to Earnings Ratio vs Industry

How does A000640's PE Ratio compare vs other companies in the KR Pharmaceuticals Industry?

1 Company	Price / Earnings	Estimated Growth	Market Cap
A007370 Jin Yang Pharmaceutical	2.4x	n/a	US$48.50m

No more companies available in this PE range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: A000640 is good value based on its Price-To-Earnings Ratio (13.9x) compared to the KR Pharmaceuticals industry average (14.6x).

Price to Earnings Ratio vs Fair Ratio

What is A000640's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A000640 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	13.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate A000640's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩2.9t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩268,500.00

-4.4%

79.2%

Medy-Tox

₩830.0b

Operates as a biopharmaceutical company in South Korea.

A086900

₩123,300.00

-10.8%

-41.6%

J2KBIO

₩54.2b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,490.00

-13.3%

n/a